|
1
|
Chen R, Sheng C, Ma R, Zhang L, Yang L and
Chen Y: PLAC1 is an independent predictor of poor survival, and
promotes cell proliferation and invasion in cervical cancer. Mol
Med Rep. 24:8002021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Auguste P: Cervical cancer screening:
Updated guidelines from the American cancer society. Am Fam
Physician. 104:314–315. 2021.PubMed/NCBI
|
|
3
|
Olusola P, Banerjee HN, Philley JV and
Dasgupta S: Human papilloma virus-associated cervical cancer and
health disparities. Cells. 8:6222019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu Z and Ma D: The precision prevention
and therapy of HPV-related cervical cancer: New concepts and
clinical implications. Cancer Med. 7:5217–5236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang XJ, Xiong Y, Ma ZB, Xia JC and Li YF:
The expression and prognostic value of protein tyrosine kinase 6 in
early-stage cervical squamous cell cancer. Chin J Cancer.
35:542016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shin WS, Shim HJ, Lee YH, Pyo M, Park JS,
Ahn SY and Lee ST: PTK6 localized at the plasma membrane promotes
cell proliferation and migration through phosphorylation of Eps8. J
Cell Biochem. 118:2887–2895. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao C, Chen Y, Zhang W, Zhang J, Xu Y, Li
W, Chen S and Deng A: Expression of protein tyrosine kinase 6
(PTK6) in nonsmall cell lung cancer and their clinical and
prognostic significance. Onco Targets Ther. 6:183–188.
2013.PubMed/NCBI
|
|
8
|
Ito K, Park SH, Katsyv I, Zhang W, De
Angelis C, Schiff R and Irie HY: PTK6 regulates growth and survival
of endocrine therapy-resistant ER+ breast cancer cells. NPJ Breast
Cancer. 3:452017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fan G, Lin G, Lucito R and Tonks NK:
Protein-tyrosine phosphatase 1B antagonized signaling by
insulin-like growth factor-1 receptor and kinase BRK/PTK6 in
ovarian cancer cells. J Biol Chem. 288:24923–24934. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ito K, Park SH, Nayak A, Byerly JH and
Irie HY: PTK6 inhibition suppresses metastases of triple-negative
breast cancer via SNAIL-dependent E-cadherin regulation. Cancer
Res. 76:4406–4417. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ono H, Basson MD and Ito H: PTK6 promotes
cancer migration and invasion in pancreatic cancer cells dependent
on ERK signaling. PLoS One. 9:e960602014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen X, Song B, Lin Y, Cao L, Feng S,
Zhang L and Wang F: PTK6 promotes hepatocellular carcinoma cell
proliferation and invasion. Am J Transl Res. 8:4354–4361.
2016.PubMed/NCBI
|
|
13
|
Bongartz H, Gille K, Hessenkemper W,
Mandel K, Lewitzky M, Feller SM and Schaper F: The multi-site
docking protein Grb2-associated binder 1 (Gab1) enhances
interleukin-6-induced MAPK-pathway activation in an SHP2-, Grb2-,
and time-dependent manner. Cell Commun Signal. 17:1352019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Simister PC and Feller SM: Order and
disorder in large multi-site docking proteins of the Gab
family-implications for signalling complex formation and inhibitor
design strategies. Mol Biosyst. 8:33–46. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vaughan TY, Verma S and Bunting KD:
Grb2-associated binding (Gab) proteins in hematopoietic and immune
cell biology. Am J Blood Res. 1:130–134. 2011.PubMed/NCBI
|
|
16
|
Shi XY, Wang H, Wang W and Gu YH:
MiR-98-5p regulates proliferation and metastasis of MCF-7 breast
cancer cells by targeting Gab2. Eur Rev Med Pharmacol Sci.
24:109142020.PubMed/NCBI
|
|
17
|
Tian J, Zhang H, Mu L, Wang M, Li X, Zhang
X, Xie E, Ma M, Wu D and Du Y: The miR-218/GAB2 axis regulates
proliferation, invasion and EMT via the PI3K/AKT/GSK-3β pathway in
prostate cancer. Exp Cell Res. 394:1121282020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fang Z, Li T, Chen W, Wu D, Qin Y, Liu M,
Wu G, He L, Li H and Gu H: Gab2 promotes cancer stem cell like
properties and metastatic growth of ovarian cancer via
downregulation of miR-200c. Exp Cell Res. 382:1114622019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Campos-Viguri GE, Peralta-Zaragoza O,
Jimenez-Wences H, Longinos-González AE, Castañón-Sánchez CA,
Ramírez-Carrillo M, Camarillo CL, Castañeda-Saucedo E,
Jiménez-López MA, Martínez-Carrillo DN and Fernández-Tilapa G:
MiR-23b-3p reduces the proliferation, migration and invasion of
cervical cancer cell lines via the reduction of c-Met expression.
Sci Rep. 10:32562020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sahu R and Pattanayak SP: Strategic
developments & future perspective on gene therapy for breast
cancer: Role of mTOR and Brk/PTK6 as molecular targets. Curr Gene
Ther. 20:237–258. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li T, Wan Y, Su Z, Li J, Han M and Zhou C:
SRF potentiates colon cancer metastasis and progression in a
microRNA-214/PTK6-dependent manner. Cancer Manag Res. 12:6477–6491.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu XL, Ye YL, Wu ZM, He QM, Tan L, Xiao
KH, Wu RY, Yu Y, Mai J, Li ZL, et al: Overexpression of PTK6
predicts poor prognosis in bladder cancer patients. J Cancer.
8:3464–3473. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Harvey AJ and Crompton MR: The Brk protein
tyrosine kinase as a therapeutic target in cancer: Opportunities
and challenges. Anticancer Drugs. 15:107–111. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng Y and Tyner AL: Context-specific
protein tyrosine kinase 6 (PTK6) signalling in prostate cancer. Eur
J Clin Invest. 43:397–404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dwyer AR, Kerkvliet CP, Krutilina RI,
Playa HC, Parke DN, Thomas WA, Smeester BA, Moriarity BS, Seagroves
TN and Lange CA: Breast tumor kinase (Brk/PTK6) mediates advanced
cancer phenotypes via SH2-domain dependent activation of RhoA and
Aryl hydrocarbon receptor (AhR) signaling. Mol Cancer Res.
19:329–345. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ostrander JH, Daniel AR, Lofgren K, Kleer
CG and Lange CA: Breast tumor kinase (protein tyrosine kinase 6)
regulates heregulin-induced activation of ERK5 and p38 MAP kinases
in breast cancer cells. Cancer Res. 67:4199–4209. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fan Y, Yang F, Cao X, Chen C, Zhang X,
Zhang X, Lin W, Wang X and Liang C: Gab1 regulates SDF-1-induced
progression via inhibition of apoptosis pathway induced by
PI3K/AKT/Bcl-2/BAX pathway in human chondrosarcoma. Tumour Biol.
37:1141–1149. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lang YD, Chen HY, Ho CM, Shih JH, Hsu EC,
Shen R, Lee YC, Chen JW, Wu CY, Yeh HW, et al: PSPC1-interchanged
interactions with PTK6 and β-catenin synergize oncogenic
subcellular translocations and tumor progression. Nat Commun.
10:57162019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zheng Y, Wang Z, Bie W, Brauer PM, Perez
White BE, Li J, Nogueira V, Raychaudhuri P, Hay N, Tonetti DA, et
al: PTK6 activation at the membrane regulates
epithelial-mesenchymal transition in prostate cancer. Cancer Res.
73:5426–5437. 2013. View Article : Google Scholar : PubMed/NCBI
|
